What is a stock summary page? Click here for an overview.
Business Description
Intra-Cellular Therapies Inc
NAICS : 325412
SIC : 2834
ISIN : BRI2TCBDR009
Share Class Description:
BSP:I2TC34: BRDRCompare
Compare
Traded in other countries / regions
ITCI.USAI2TC34.Brazil23I.GermanyITCI.Mexico IPO Date
2023-07-24Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. It maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 58.95 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 38.13 | |||||
| Beneish M-Score | -2.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 87.2 | |||||
| 3-Year EBITDA Growth Rate | 31.5 | |||||
| 3-Year EPS without NRI Growth Rate | 41 | |||||
| 3-Year FCF Growth Rate | 39.4 | |||||
| 3-Year Book Growth Rate | 28.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 48.64 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 99.24 | |||||
| 9-Day RSI | 94.28 | |||||
| 14-Day RSI | 88.36 | |||||
| 3-1 Month Momentum % | 47.29 | |||||
| 6-1 Month Momentum % | 86.22 | |||||
| 12-1 Month Momentum % | 150.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.36 | |||||
| Quick Ratio | 6.23 | |||||
| Cash Ratio | 4.87 | |||||
| Days Inventory | 124.95 | |||||
| Days Sales Outstanding | 75.41 | |||||
| Days Payable | 98.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward Dividend Yield % | 97.47 | |||||
| 3-Year Average Share Buyback Ratio | -9.1 | |||||
| Shareholder Yield % | -3.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.63 | |||||
| Operating Margin % | -17.15 | |||||
| Net Margin % | -10.97 | |||||
| FCF Margin % | -10.43 | |||||
| ROE % | -8.07 | |||||
| ROA % | -6.8 | |||||
| ROIC % | -69.8 | |||||
| 3-Year ROIIC % | 114.21 | |||||
| ROC (Joel Greenblatt) % | -116.5 | |||||
| ROCE % | -12.43 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 668.94 | |||||
| PS Ratio | 20.03 | |||||
| PB Ratio | 12.2 | |||||
| Price-to-Tangible-Book | 12.2 | |||||
| EV-to-EBIT | -111.67 | |||||
| EV-to-Forward-EBIT | 22.1 | |||||
| EV-to-EBITDA | -112.15 | |||||
| EV-to-Forward-EBITDA | 47.6 | |||||
| EV-to-Revenue | 19.16 | |||||
| EV-to-Forward-Revenue | 13.7 | |||||
| EV-to-FCF | -178.51 | |||||
| Price-to-GF-Value | 1.02 | |||||
| Price-to-Net-Current-Asset-Value | 12.86 | |||||
| Price-to-Net-Cash | 17.89 | |||||
| Earnings Yield (Greenblatt) % | -0.89 | |||||
| FCF Yield % | -0.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intra-Cellular Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 3,775.394 | ||
| EPS (TTM) (R$) | -0.671 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 56.14 | ||
| 14-Day RSI | 88.36 | ||
| 14-Day ATR (R$) | 0.139972 | ||
| 20-Day SMA (R$) | 124.752 | ||
| 12-1 Month Momentum % | 150.51 | ||
| 52-Week Range (R$) | 49.53 - 129.99 | ||
| Shares Outstanding (Mil) | 639.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intra-Cellular Therapies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intra-Cellular Therapies Inc Stock Events
| Event | Date | Price (R$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intra-Cellular Therapies Inc Frequently Asked Questions
What is Intra-Cellular Therapies Inc(BSP:I2TC34)'s stock price today?
The current price of BSP:I2TC34 is R$125.76. The 52 week high of BSP:I2TC34 is R$129.99 and 52 week low is R$49.53.
When is next earnings date of Intra-Cellular Therapies Inc(BSP:I2TC34)?
The next earnings date of Intra-Cellular Therapies Inc(BSP:I2TC34) is 2025-05-07 Est..
Does Intra-Cellular Therapies Inc(BSP:I2TC34) pay dividends? If so, how much?
Intra-Cellular Therapies Inc(BSP:I2TC34) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers